Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XED-60
- Development stage
- Unknown
- Lead developer
- Lion Corporation
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
XED-60 is an investigational small molecule topical ophthalmic agent developed by Lion Corporation for the treatment of dry eye disease. It is currently in Phase 2 clinical development in Japan, where it is being evaluated as an eye drop formulation administered six times daily for a duration of four weeks. The clinical trial (jRCT1080222777) focuses on patients aged 15 years and older diagnosed with dry eye according to the Japanese Dry Eye Research Group criteria. While the specific molecular target of XED-60 has not been publicly disclosed, it is categorized as a potential mucin production promoter intended to stabilize the tear film and improve the health of the ocular surface.
Beyond the preview
Go deeper on XED-60.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XED-60.